Global Markets for Enzyme Inhibitors
- December 2017 •
- 246 pages •
- Report ID: 5251938
• The global market for enzyme inhibitors should reach $179.9 billion by 2022 from $168 billion in 2017 at a compound annual growth rate (CAGR) of 1.4%, from 2017 to 2022.
• The kinase inhibitors market is expected to grow from $54.9 billion in 2017 to $80 billion in 2022 at a CAGR of 7.8% for the period 2017-2022.
• The reverse transcriptase inhibitors market is expected to grow from $16.9 billion in 2017 to $20.7 billion in 2022 at a CAGR of 4.1% for the period 2017-2022.
Chapter 1: Introduction
Study Goals and Objectives
Enzyme inhibitors are used as therapeutic agents to treat a variety of diseases. These agents bind with enzymes in body and decrease the enzymatic activity of that specific enzyme. BCC Research’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for various enzyme inhibitors. The key objective is to present a comprehensive analysis and future direction of enzyme inhibitors as an important therapeutic/diagnostic agent.
This report explores present and future strategies within the enzyme inhibitors market, which includes proton pump inhibitors, protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 inhibitors, neuraminidase inhibitors, angiotensinconverting enzyme inhibitors, poly(ADP-ribose) polymerase (PARP) inhibitors, xanthine oxidase inhibitors (XOIs), phosphodiesterase type 4 (PDE4) inhibitors, cyclooxygenase inhibitors, 5-alpha reductase (5-ARI) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, integrase inhibitors, monoamine oxidase inhibitors (MAOIs), proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and acetylcholinesterase inhibitors (AChEIs).
The improvisation of the market, the setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these enzyme inhibitors are also portrayed.
A detailed analysis and structure of enzyme inhibitors industry is provided. The revenues are broken down by the region. The sales figures are estimated for the five-year period from 2017 through 2022.
Applications for various enzyme inhibitors are also discussed separately in the report, with emphasis of the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.
Reasons for Doing This Study
Enzymes are responsible for many of the physiological functions in human body. They are involved in regulation of metabolic pathways and play active role in the life processes of an organism. Thus, the enzyme inhibitors can be used either to regulate the metabolic functions or to inactivate/kill the infectious agents such as viruses. The enzyme activity can be blocked reversibly or irreversibly.
The extensive research in the field of enzyme inhibitors has revealed their target specific functionality in being able to provide therapeutic treatments for various chronic diseases. Even though modern industries have now begun to explore the advantages of enzyme inhibitors in their production and processes, the global enzyme inhibitor market in recent years (2013–2017) is going through a rough patch. Some of the reasons include the expiry of patents of many popular branded enzyme inhibitor drugs (which have led to an inflow of generics), price erosion and competition and the launch of many novel products particularly among the protease inhibitors, reverse transcriptase inhibitors and kinase inhibitors category that have attracted increased competition among products.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type in light of the new technologies, growing competition and changing customer needs.
Scope of Report
Enzyme inhibitors drugs are drugs that help to treat chronic diseases such as cardiovascular disease, gastrointestinal disease, acquired immunodeficiency syndrome, cancer, hepatitis, men’s-health-related conditions (erectile dysfunction, benign prostatic hyperplasia, alopecia), diabetes and various others (rheumatoid arthritis, psoriasis, Parkinson’s disease, influenza, etc.). This report focuses on the global market of enzyme inhibitor drug products and provides an updated review including its applications in various arenas of disease sectors. The scope of the study is global.
BCC Research analyzes each market and its application, new products and advancements, market projections and market shares. This study surveys each market in all the geographic regions including North America, Europe and emerging markets. The emerging market category covers all countries such as India, China, South Korea, Taiwan, Africa, Australia, New Zealand, Canada, Latin America and so forth.
Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the enzyme inhibitor drugs industry. Some of the major players of the market include, F. HoffmannLa Roche, Novartis AG, Pfizer Inc., AstraZeneca plc, Merck & Co., Gilead Sciences, Janssen Pharmaceuticals, ViiV Healthcare, Eli Lilly and Co., Takeda Pharmaceuticals, Bayer AG, Amgen Inc., AbbVie , Eisai Inc., Teva Pharmaceuticals Inc. and others.
BCC Research analyzes the current market situation by discussing the market drivers, restraints, challenges and opportunities. The market projections and market shares are examined for each region and type. The latest news pieces including new products, mergers and acquisitions in each market are also dealt with in sufficient detail. Also included in the report are relevant patent analysis and comprehensive profiles of companies that are dominant in the enzyme inhibitors industry.
The period of the current report saw an enormous number of new approvals and new indication approvals. New enzyme inhibitor categories gained entries in the market. In comparison with the last report, therefore, a number of new enzyme inhibitor types have been included in this report.
They are integrase inhibitors, PCSK9 inhibitors, PARP inhibitors, PDE4 inhibitors, DPP-4 inhibitors and SGLT-2 inhibitors. Certain other categories that had mentionable markets were also included such as AChEIs, 5ARI inhibitors, XOIs and MAOIs. The market had started to decline due to patent expiries since 2010– 2011, and the trend was seen to accelerate during the period of the current report.
Excluded from this report are enzyme inhibitors used in other markets of diagnostics, pesticides and biotechnology.
Many companies were surveyed to obtain data for this study. Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and industries in various disease sectors. Data were gathered from various industry sources. BCC Research spoke with officials within the industry, as well as consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts.
Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.
Both primary and secondary research methodologies were used in preparing this study. BCC research conducted a comprehensive literature search, which included technical newsletters, journals and many other sources. Data were collected through interviews and correspondence with manufacturers of enzyme inhibitors technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, as well as market trends.
In this report, the geographic regions considered for market analysis include, and only include:
- Albania, Austria, Czech Republic, Denmark, France, Germany, Hungary, Italy, Luxembourg, Serbia and Montenegro,
- Iceland, Malta, Slovakia, Belgium, Estonia, Ireland, Netherlands, Slovenia, Bosnia and Herzegovina, Finland, Israel, Norway, Spain, Bulgaria, Poland, Sweden, Croatia, Latvia, Portugal, Switzerland, Cyprus, Greece, Lithuania, Romania, UK.
- South Korea.
- New Zealand.
- Latin America.
Enzyme Inhibitors, BY TYPE
Proton Pump Inhibitors
Reverse Transcriptase Inhibitors
Phosphodiesterase Type 5 Inhibitors
Angiotensin-Converting Enzyme Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
Xanthine Oxidase Inhibitors
Phosphodiesterase Type 4 Inhibitors
5-Alpha Reductase Inhibitors
Dipeptidyl Peptidase 4 Inhibitors
Sodium-Glucose CoTransporter-2 Inhibitors
Monoamine Oxidase Inhibitors
Enzyme Inhibitors, by Application
Cardiovascular Disease (CVD)
Gastrointestinal (GI) Disease
Acquired Immunodeficiency Syndrome (AIDS)
Chapter 2: Summary and Highlights
Enzyme inhibitors in the therapeutic category are used for the treatment of a number of diseases. The diseases once considered difficult to treat are now treatable with enzyme inhibitor drugs. One such disease is hepatitis C (HCV).
There were only two drugs approved by the U.S. Food and Drug Administration for HCV treatment, that is, pegylated interferon and ribavirin. The launch of protease inhibitor drugs by Gilead Sciences, namely Sovaldi (launched in December 2013) and Harvoni (launched in October 2014), proved to be a boon to the patients suffering from this deadly disease. The development of novel reverse transcriptase inhibitors and integrase inhibitors have also aided in effective therapeutic options for human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS).
Cancer is a global disease. Pharmaceutical companies have invested millions of dollars in the research and development of innovative medicines for cancer. The drugs now available for targeted therapy of various types of cancers including breast cancer, lung cancer, ovarian cancer and colorectal cancer belong to the category of kinase inhibitors. Herceptin (Roche Holding AG) and Tagrisso (AstraZeneca plc) are popular names in this category. Poly(ADP-ribose) polymerase (PARP) inhibitors are a novel class of anticancer drugs that are gaining market share.
The enzyme inhibitors market includes the following segments:
- Proton pump inhibitors (PPIs).
- Protease inhibitors.
- Reverse transcriptase inhibitors.
- Kinase inhibitors.
- Cyclooxygenase (COX) inhibitors.
- Aromatase inhibitors.
- Phosphodiesterase type 5 (PDE5) inhibitors.
- Neuraminidase inhibitors.
- Angiotensin-converting enzyme (ACE) inhibitors.
- PARP inhibitors.
- Xanthine oxidase inhibitors (XOIs).
- Phosphodiesterase type 4 (PDE4) inhibitors.
- Cyclooxygenase-2 (COX-2) inhibitors.
- 5-alpha reductase inhibitors (5-ARIs).
- Dipeptidyl peptidase-4 (DPP-4) inhibitors or gliptins.
- Sodium-glucose co-transporter-2 (SGLT-2) inhibitors or gliflozins.
- Integrase inhibitors.
- Monoamine oxidase inhibitors (MAOIs).
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
- Acetylcholinesterase inhibitors.
Gastrointestinal (GI) disease, cardiovascular disease (CVD), inflammatory disorders, rheumatoid arthritis, neurological disorders of depression, Parkinson’s disease, Alzheimer’s disease and diabetes are other diseases that have therapeutic options available in the form of enzyme inhibitor drugs.
North America has the highest market share in the global enzyme inhibitors market. The presence of big pharmaceutical companies in this region, developed regulatory and healthcare infrastructure and stronger intellectual property protection are favorable factors for the growth of the enzyme inhibitors market in the U.S. The prevalence of many chronic diseases complemented by an aging population also drives the market in the U.S. Europe, particularly the U.K., is a popular location for the clinical trials.
However, the decision of the U.K. government to leave the E.U., termed as “Brexit,” might prove a deterrent for investors in the enzyme inhibitors market in this region. The emerging markets, particularly the Asia-Pacific region, have shown growth potential in the recent years. The rising affluence in these countries has brought a change in the lifestyles of the populations. Consequently, there have been rising incidences of diseases such as obesity, diabetes and cardiovascular disorders. Countries of Africa and other developing countries are still battling with some of the highest proportions of HIV/AIDS and hepatitis. The need for affordable and innovative medicines is the growth driver for the enzyme inhibitors market in the low- and middle-income developing countries of the emerging markets.